Selective Inhibition Of Tyrosine Kinase 2 Pathway For Psoriasis Treatment

Synopsis Psoriasis is a chronic long-lasting skin condition that results from an overactive immune system. Tyrosine kinase 2 (Tyk2) is an intracellular enzyme that participates in signal transducer and activator of transcription (STAT) signaling pathway to induce production of inflammatory cytokines. These cytokines are involved in pathological responses of various immune-mediated disorders, including psoriasis. Preclinical and a phase I trial have shown preliminary evidence of the effect of a selective Tyrosine kinase 2 (Tyk2) inhibitor, BMS-986165 on psoriasis.

This week’s “ MED FACT ” discusses a randomized, double-blind, placebo-controlled trial from The New England Journal of Medicine, ‘ Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis ’ Oct 2018. Authors : Kim Papp, Kenneth Gordon, Diamant Thaci, et al. Key Takeaways Oral administration of BMS-986165, a…